| Management target | Revenue 20.0% |
|---|
| Revenue growth | Q2 revenue +17% YoY to ₹83.1 Cr; H1 +12%. |
|---|---|
| Margins | Q2 EBITDA 21.6%; 25%+ two-year aim; polymer costs volatile. |
| Demand visibility | Steriport demand strong in ICU and critical care; SVP demand unquantified. |
| Management confidence | Over-optimistic: bold targets, deflects on SVP numbers. |
Growth
Q2 revenue +17%, EBITDA +22%. H1 revenue +12% but EBITDA only +8%, so the quality story weakens.
Outlook
FY27 revenue ₹420–430 Cr. SVP ₹16 Cr in FY28. Two-year aim: 20%+ revenue CAGR, 25%+ EBITDA margin.
Risks
FY27 ₹420–430 Cr needs ~₹270 Cr in H2 versus ~₹83 Cr quarterly run-rate. SVP line slipped to Q1 FY28.
Last quarter's promises, checked
Delivered
- Q2 rev 'needle may not move much' (Q1 ₹69 Cr) → ₹83.1 Cr, +17% YoY (= BEAT)
Partly delivered
- SteriPort L3 live 24–25 Aug → live Sep 2026 (= PARTIAL)
- Debt ₹30–35 Cr/yr cut → ₹35 Cr/yr planned, actual unreported (= PARTIAL)
Missed
- Console margin +4–5% post Line 3 → Q2 EBITDA 21.6% vs Q1 ~22%, no expansion (= MISS)
- SVP live Q4 FY27 → slipped to Q1 FY28 (= MISS)
- D/E falling from 1.06 → 1.1x (= MISS)
Earnings Call Transcript filed with NSE, NSE: AMANTA. Summary written with AI assistance from the document.
Amanta Healthcare Ltd: key numbers
- Share price
- ₹185.80
- Market cap
- ₹721.5 Cr
- Revenue (annual)
- ₹287.7 Cr
- Net profit (annual)
- ₹14.88 Cr
- P/E (TTM)
- 39.4×Sector 41.3×
- Promoter holding
- 63.80%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amanta Healthcare Ltd
All →Amanta Healthcare Investor Presentation: Key Takeaways
Q2FY27 revenue ₹83.1 Cr (+17.3% YoY), EBITDA ₹17.95 Cr (21.6% margin), PAT ₹4.86 Cr. H1 revenue ₹151.9 Cr, PAT ₹8.2 Cr. SteriPort Line 3 commissioned September 2026.
- Call
- Guides 20% growth
Amanta Healthcare Results Update
Amanta Healthcare reported Q2FY27 revenue of ₹83.13 crore and PAT of ₹4.86 crore, both up sharply YoY. SteriPort Line 3 was commissioned, raising bottle capacity to 11.6 crore.
- SteriPort bottle capacity
- 11.6 crore bottles
Amanta Healthcare Q2 FY27 Results: Net Profit ₹4.9 Cr, Up 308.3% YoY
Amanta Healthcare Ltd reported revenue from operations of ₹83.1 Cr (+17.2% YoY) and net profit of ₹4.9 Cr (+308.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹4.9 Cr · +308.3% YoY
Amanta Healthcare Other Announcement
Amanta Healthcare's quarterly shareholding pattern as at 30 Sep 2026 shows promoter and promoter group holding at 31.33%. The filing notes a gift-based promoter group addition, but is a routine periodic disclosure.
Amanta Healthcare Management Change
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Amanta Healthcare Board Meeting Date
Amanta Healthcare intimated a Board Meeting scheduled for 3 Nov 2026 to approve Q1 & H1 FY27 unaudited results. Trading window reopens on 6 Nov 2026.